| CAS NO: | 953778-58-0 |
| 规格: | ≥98% |
| 包装 | 价格(元) |
| 5mg | 电议 |
| 10mg | 电议 |
| 25mg | 电议 |
| 50mg | 电议 |
| 100mg | 电议 |
| 250mg | 电议 |
| 500mg | 电议 |
| Molecular Weight (MW) | 380.41 |
|---|---|
| Formula | C20H23F3N2O2 |
| CAS No. | 953778-58-0 |
| Storage | -20℃ for 3 years in powder form |
| -80℃ for 2 years in solvent | |
| Solubility (In vitro) | DMSO: 10 mM |
| Water: <1 mg/mL | |
| Ethanol: <1 mg/mL | |
| Chemical Name | (R)-2-(4-isopropylphenyl)-N-(1-(5-(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl)acetamide |
| Synonyms | MK-8998; MK8998; MK 8998 |
| In Vitro | In vitro activity: MK-8998 is a potent and selective antagonist of the T-type calcium channel that is being investigated as a potential new therapy for the treatment of schizophrenia. Because MK-8998 does not block D2, 5HT2a, muscarinic, or histaminic receptors, it has the potential for a substantially improved side effect profile compared with currently available atypical antipsychotics. Kinase Assay:MK-8998 is a potent and selective antagonist of the T-type calcium channel. Cell Assay: |
|---|---|
| In Vivo | MK-8998 is not effective in treating acutely psychotic inpatients with schizophrenia. There are no significant differences between either MK-8998 or olanzapine versus placebo at any time point. MK-8998 and olanzapine are generally well tolerated but are associated with a higher percentage of adverse events compared with placebo |
| Animal model | |
| Formulation & Dosage | |
| References | Hum Psychopharmacol. 2013 Mar;28(2):124-33. |
m.cnreagent.com